Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy

Gilead Sciences’ Kite Pharma has become the first drugmaker to get FDA approval to use a CAR-T therapy after just one earlier systemic therapy, moving the approach up the treatment pathway.